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Effects of lovastatin on expression of cell cycle regulatory pro- reported that HMG-CoA reductase inhibitors diminish
teins in vascular smooth muscle cells. the prenylation of G-g subunits and p21ras [3] and inhibit
Background. The sequential appearance of cyclins D and E VSMC proliferation [4]. Cell proliferation is regulatedis thought to initiate subsequent DNA synthesis in proliferating
at the level of the cell cycle by specific cyclins, cyclin-cells. Previous studies have reported that DNA synthesis in
dependent kinases (CDKs), and cyclin kinase inhibitorscultured rat vascular smooth muscle cells (VSMCs) was sup-
pressed by the HMG-CoA reductase inhibitor lovastatin. The (CKIs) [5–7]. In order to clarify the effects of HMG-
effects of lovastatin on cell cycle regulatory proteins in prolifer- CoA reductase inhibitors on the VSMC cell cycle, we
ating VSMCs, however, are largely unknown. Thus, we investi- investigated the effects of lovastatin, an HMG-CoA re-gated the sequential expression of cyclin D1, cyclin E, cyclin-
ductase inhibitor, on DNA synthesis and the expressiondependent kinase (CDK) 4, CDK2, and p27Kip1 in cultured
of cyclins D and E, CDKs 2 and 4, and the CKI p27Kip1.rat VSMCs stimulated by platelet-derived growth factor
(PDGF)-BB in the presence or absence of lovastatin.
Methods. Quiescent VSMCs, with and without lovastatin
(20 mm) pretreatment for nine hours, were stimulated by METHODS
PDGF-BB (25 ng/ml). The incorporation of tritiated thymidine Cell culturewas done to assess DNA synthesis. VSMC lysates were ob-
tained every 6 hours for up to 36 hours after stimulation and Cultured rat VSMCs at the fifth and seventh passage
were subjected to sodium dodecyl sulfate-polyacrylamide gel in 175 cm2 flasks were studied. Subconfluent cells were
electrophoresis and Western blot analysis using relevant poly- synchronized to quiescence by culture in medium contain-clonal antibodies. Autoradiograms were analyzed using a den-
ing 0.2% heat-inactivated fetal bovine serum (HIFBS)sitometer.
for 48 hours. Some cells were then stimulated by PDGF-Results. The peak expression of cyclins D1 and E occurred
at 18 and 30 hours of PDGF stimulation, respectively. Concom- BB (25 ng/ml) in 0.2% HIFBS, whereas control cells
itant expression of CDK4 and CDK2 was also observed. The remained in 0.2% HIFBS. To study the effects of lova-
expression of p27Kip1, by contrast, was reduced in association statin, some VSMCs were pretreated with lovastatin (20with DNA synthesis. Lovastatin suppressed DNA synthesis
mm in 0.2% HIFBS) during the last nine hours of synchro-and reduced the expression of cyclin D1 and cyclin E, whereas
nization. Lovastatin did not alter cell shape or viabilityp27Kip1 expression was strongly induced by lovastatin pre-
treatment. CDK4 and CDK2 expression was unaffected by (viability was more than 95%).
lovastatin treatment.
Conclusions. PDGF-BB induces cyclins D1 and E prior to DNA synthesis
the onset of DNA synthesis in VSMCs. Lovastatin may sup-
Quiescent VSMCs were dispersed in 96-well multi-press DNA synthesis in VSMCs by inducing p27Kip1 and re-
plates under the same conditions described earlier. Dur-ducing expression of cyclins D1 and E.
ing the last six hours of incubation, 1 mCi of [3H]TdR
(20.0 Ci/mmol; New England Nuclear, Boston, MA,
USA) was added to respective wells, and [3H]TdR incor-Intimal hyperplasia is a histologically characteristic
poration was measured with a liquid scintillation counterfeature in the arterial tree of chronic renal allograft rejec-
and used as an index of DNA synthesis.tion [1]. The development of this lesion involves the
proliferation and migration of vascular smooth muscle
Cell lysatecells (VSMCs) caused by mitogens such as platelet-
Vascular smooth muscle cells were rinsed three timesderived growth factor (PDGF) [2]. Previous studies have
with cold phosphate-buffered saline and lysed at 0, 6,
12, 18, 24, 30, and 36 hours of PDGF stimulation. The
Key words: CDK2, CDK4, cyclin D1, cyclin E, DNA synthesis. lysate solution contained 1% Triton X-100, 10% glyc-
erol, 20 mm HEPES, 100 mm NaCl, 10 mg/ml leupeptin, 1999 by the International Society of Nephrology
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stimulated by PDGF appeared to begin between 18 and
24 hours after exposure to PDGF and increased progres-
sively thereafter (Fig. 1). Lovastatin suppressed DNA
synthesis in PDGF-stimulated VSMCs.
Increased expression of cyclin D1 was found at 6 hours,
and peak expression of cyclin D1 was observed at 18
hours after PDGF stimulation (Fig. 2A). Lovastatin sup-
pressed cyclin D1 expression at 6 and 12 hours, whereas
the peak expression of cyclin D1 at 18 hours was similar
to that in cells not treated with lovastatin. Cyclin D1
expression at 36 hours in PDGF-stimulated VSMCs, re-
gardless of whether cells were exposed to lovastatin,
was similar to that in control cells (Fig. 2A). Cyclin E
expression in PDGF-stimulated VSMCs increased pro-
Fig. 1. DNA synthesis in cultured rat vascular smooth muscle cells
gressively to a peak at 30 hours (Fig. 2B). Lovastatin(VSMCs) stimulated by platelet-derived growth factor (PDGF). DNA
synthesis was suppressed by lovastatin pretreatment for nine hours prior reduced the peak cyclin E expression by more than 40%.
to PDGF stimulation. Triangles, VSMCs 1 PDGF 25 ng/ml; squares, A time-dependent increase in CDK4 expression was
VSMCs 1 lovastatin (20 mm) pretreatment prior to PDGF stimulation;
found up to a peak at 24 hours of PDGF stimulation,circles, control VSMCs maintained in 0.2% heat-inactivated fetal bovine
serum. Data represent means 6 sd of three experiments. followed by a subsequent decline (Fig. 2C). Lovastatin
did not affect CDK4 expression. CDK2 expression in
PDGF-stimulated VSMCs increased throughout the ex-
perimental period (Fig. 2D). At 36 hours, CDK2 expres-10 mg/ml antipain, 10 mg/ml pepstatin, 0.1 mm sodium
sion was increased nearly threefold compared with thatorthovanadate, and 50 mm sodium fluoride. After centrif-
in control cells. Lovastatin did not suppress CDK2 ex-ugation at 12,000 r.p.m. for five minutes at 48C, the pro-
pression.tein concentration of the supernatant was measured us-
Quiescent VSMCs at the end of the 48-hour synchroni-ing the bicinchoninic acid assay (Pierce Chemical, Rock-
zation period displayed high expression of the CKIford, IL, USA).
p27Kip1 (Fig. 2E). Lovastatin pretreatment increased
p27 expression by 100%. Exposure of VSMCs to PDGFWestern blot analysis
caused a progressive decline in p27 expression through-Fifty mg of protein from each cell lysate was separated
out the experimental period.on 12% sodium dodecyl sulfate-polyacrylamide gel elec-
trophoresis gels and transferred to polyvinylidene fluo-
ride (PVDF) membranes (Millipore, Bedford, MA, DISCUSSION
USA). After blocking with 0.5% casein, the membranes
Cyclins and CDKs constitute the major positive cell
were hybridized with rabbit primary polyclonal antibod-
cycle regulatory proteins [6–8]. Cyclins D and E are
ies to cyclins, CDKs, and p27Kip1 for 60 minutes at room
synthesized in the G1 phase, and the latter is essentialtemperature, followed by hybridization with secondary
for G1 to S phase transition [9]. Cyclins D and E bindhorseradish peroxidase-conjugated goat antirabbit anti-
to CDK4 and CDK2, respectively, leading to the inacti-body (1:20,000; Chemicon International, Temecula, CA,
vation of retinoblastoma protein and progression of theUSA) for 60 minutes at room temperature. The primary
cell cycle [10, 11]. Cyclin D-CDK4 complexes are inhib-antibodies used in this study were cyclin D1 (1:1500;
ited by all CKIs, whereas cyclin E-CDK2 complexes areUpstate Biotechnology, Lake Placid, NY, USA), cyclin
inhibited by the CKI p27Kip1, causing cells to remainE (1:1000; Santa Cruz Biotechnology, Santa Cruz, CA,
at the G1 phase and quiescent [8].USA), CDK4 (1:3000; Santa Cruz Biotechnology),
In this study, DNA synthesis appeared to begin be-CDK2 (1:500; Santa Cruz Biotechnology), and p27
tween 18 and 24 hours of exposure of VSMCs to PDGF.(1:1000; Santa Cruz Biotechnology). Autoradiograms of
Prior to the onset of DNA synthesis, VSMCs displayedthe Western blots were analyzed using a Personal Densi-
increased expression of cyclins D1 and E. Cyclin D1tometer SI and the ImageQuaNT program (Molecular
expression was increased at 6 hours of PDGF stimula-Dynamics, Sunnyvale, CA, USA).
tion, peaked at 18 hours of stimulation, and declined
thereafter. Cyclin E expression increased steadily to a
RESULTS peak at 30 hours and then declined by 36 hours. The
observed time course of changes in cyclins D1 and EThymidine incorporation in control, quiescent VSMCs
was consistent, therefore, with the regulatory roles ofremained at a low and constant level throughout the
experimental period (Fig. 1). DNA synthesis in VSMCs these proteins in the cell cycle. Cyclin D1 is synthesized
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Fig. 2. Western blot analysis of expression of cell cycle regulatory proteins in cultured rat vascular smooth muscle cells (VSMCs). (A) Cyclin D1.
(B) Cyclin E. (C) CDK 4. (D) CDK2. (E) p27Kip1. Molecular weight of each cell-cycle protein is cyclin D1, 36 kDa; cyclin E, 42 and 50 kDa;
CDK4, 34 kDa; CDK2, 33 kDa. Culture conditions are (a) control VSMCs incubated in 0.2% heat-inactivated fetal bovine serum; (b) VSMCs 1
PDGF (25 ng/ml); and (c) VSMCs 1 lovastatin (20 mm) pretreatment for nine hours prior to PDGF stimulation. Optical density (O.D.) of the
autoradiogram at time 0 was determined as baseline (O.D. 5 1.0). Data in graphs represent the ratios of O.D. values.
when quiescent (G0) cells are stimulated to enter the G1 of these actions of lovastatin may have been responsible
for the effect of lovastatin to suppress DNA synthesisphase, and cyclin E is necessary for transition from the
in VSMCs exposed to PDGF. By contrast, lovastatinG1 to the S phase, the phase of DNA synthesis.
suppression of DNA synthesis did not appear to dependAssociated with increased expression of cyclins D1
on a reduction in CDK4 or CDK2 expression.and E in PDGF-stimulated VSMCs was enhanced ex-
pression of the respective CDKs to which the cyclins
ACKNOWLEDGMENTSbind. Indeed, the time course of increased CDK4 and
CDK2 expression paralleled the time course of increased This work was supported, in part, by the Uehara Memorial Founda-
tion.cyclin D1 and cyclin E expression, respectively. PDGF
stimulation of VSMCs also caused a rapid decline in Reprint requests to Michael P. O’Donnell, Ph.D., Minneapolis Medi-
cal Research Foundation, 914 South Eighth Street, Minneapolis, Minne-expression of the CDK inhibitor p27Kip1, consistent
sota 55404, USA.with release of cells from G0 and their entry into the cell E-mail: mod19@mail.idt.net
cycle.
Lovastatin pretreatment of VSMCs prior to PDGF REFERENCES
stimulation markedly enhanced the expression of
1. Geraghty JG, Stoltenberg RL, Sollinger HW, Hullett DA:p27Kip1, reduced the early (6 to 12 hr) expression of Vascular smooth muscle cells and neointimal hyperplasia in chronic
transplant rejection. Transplantation 62:502–509, 1996cyclin D1, and reduced cyclin E expression. One or more
Oda et al: Lovastatin effects on cell cycle proteins S-205
2. Myllarniemi M, Calderon L, Lemstrom K, Buchdunger E, 6. Sherr CJ: G1 phase progression: Cycling on cue. Cell 79:551–555,
1994Hayry P: Inhibition of platelet-derived growth factor receptor
tyrosine kinase inhibits vascular smooth muscle cell migration and 7. Morgan DO: Principles of CDK regulation. Nature 374:131–134,
1995proliferation. FASEB J 11:1119–1126, 1997
3. Pomerantz KB, Lander HM, Summers B, Robishaw JD, Bal- 8. Sherr CJ, Roberts JM: Inhibitors of mammalian G1 cyclin-depen-
dent kinases. Genes Dev 9:1149–1163, 1995cueva E, Hajjar DP: G-protein-mediated signaling in cholesterol-
enriched arterial smooth muscle cells. I. Reduced membrane-asso- 9. Ohtsubo M, Theodoras AM, Schumacher J, Roberts JM, Pa-
gano M: Human cyclin E, a nuclear protein essential for the G1-ciated G-protein content due to diminished isoprenylation of
G-gamma subunits and p21ras. Biochemistry 36:9523–9531, 1997 to-S phase transition. Mol Cell Biol 15:2612–2624, 1995
10. Weinberg RA: The retinoblastoma protein and the cell cycle. Cell4. Negre-Aminou P, van Erck M, van Thiel GC, van Leeuwen RE,
Cohen LH: Inhibition of proliferation of human smooth muscle 81:323–330, 1995
11. Arita Y, Buffolino P, Coppock DL: Regulation of the cell cyclecells by various HMG-CoA reductase inhibitors: Comparison with
other human cell types. Biochim Biophys Acta 1345:259–268, 1997 at the G2/M boundary in metastatic melanoma cells by 12-O-
tetradecanoyl phorbol-13-acetate (TPA) by blocking p34cdc2 ki-5. Pardee AB: G1 events and regulation of cell proliferation. Science
246:603–608, 1989 nase activity. Exp Cell Res 242:381–390, 1998
